News
Aug, 07, 2015 - News

Denka Seiken: Announcement of Acquisition of Shares (Ownership) in ICON Genetics GmbH, a German Bio-pharmaceutical R&D Company

Denka Seiken: Announcement of Acquisition of Shares (Ownership) in ICON Genetics GmbH, a German Bio-pharmaceutical R&D Company

Company Name: DENKI KAGAKU KOGYO KABUSHIKI KAISHA

Name of Representative: Shinsuke Yoshitaka, President and CEO (Code 4061: TSE 1st Section)

Contact: Noriyuki Shimizu, CSR & Corporate Communications Dept. (Tel: 03-5290-5511 E-Mail: csr-koho@denka.co.jp)

Announcement of Acquisition of Shares (Ownership) in Icon Genetics GmbH, a German Bio-pharmaceutical R&D Company DENKI KAGAKU KOGYO KABUSHIKI KAISHA (Headquartered at: Chuo-ku, Tokyo; Shinsuke Yoshitaka, President & CEO, hereinafter „Denka“) is pleased to announce that, it has agreed and entered into a share transfer agreement on August 6, 2015 with Nomad Bioscience GmbH (Headquartered at: Munich, Germany; Prof. Dr. Yuri Gleba, CEO, hereinafter „Nomad“) regarding its acquisition (the „Acquisition“) in two phases of all of the shares of Icon Genetics GmbH (Headquartered at: Halle, Sachsen-Anhalt, Germany; Prof. Dr. Yuri Gleba, CEO, hereinafter „Icon“), a German Bio-pharmaceutical R&D Company. Nomad is the parent company of Icon.

Download Pdf

Related articles

Jun, 06, 2023 - News

NOMAD Bioscience Extends Agreements with Plant Biomass Producers in Extremadura Spain

NOMAD Bioscience Extends Agreements with Plant Biomass Producers in Extremadura Spain Munich, June, 2023 – NOMAD BIOSCIENCE GmbH, Munich, Germany…
Jan, 24, 2023 - News

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement Nomad Bioscience GmbH, Munich,…
Okt, 11, 2022 - News

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins Munich, October 2022 – NOMAD Bioscience GmbH has…
Apr, 20, 2022 - News

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas NOMADS UAB, Lithuania,…